CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

• Published in: Blood Vol. 128; no. 22; p. 384
• Main Authors: Sherbenou, Daniel W., Aftab, Blake T., Su, Yang, Behrens, Christopher R., Wiita, Arun P., Logan, Aaron C., Acosta-Alvear, Diego, Hann, Byron C., Walter, Peter, Wu, Xiaobo, Atkinson, John P., Wolf, Jeffrey L., Martin, Thomas G., Liu, Bin
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.12.2016

Background: Multiple myeloma (MM) is incurable by standard approaches, with relapse and development of treatment resistance inevitable in all patients. We previously identified a panel of novel macropinocytosing human monoclonal antibodies against CD46 by phage antibody library display and optimized...